On August 12, 2026, Outlook Therapeutics entered into an underwriting agreement for a public offering of 55,555,556 shares of common stock and accompanying warrants to purchase up to the same number of shares. The combined public offering price is $0.99 per share and warrant. Gross proceeds are estimated at approximately $55.0 million before deducting underwriting discounts and commissions. Each warrant carries an initial exercise price of $1.10 and expires five years from issuance. The underwriters exercised their option to purchase additional warrants for 8,333,333 shares. Key insiders, including CEO Robert Jahr and CFO Lawrence Kenyon, along with largest stockholder GMS Ventures, purchased shares in the offering. Outlook Therapeutics operates in the biotechnology industry.
